Key Highlights
- BioNTech shares are up approximately 19.64 percent to $110.97, from Tuesday's close of $92.75.
- The surge is driven by a sector-wide rally in mRNA and oncology-focused biotech names following Moderna and Merck's positive late-stage melanoma trial results announced this morning.
- The move also follows BioNTech's second-quarter report, which showed Revenue beating expectations despite fading COVID-19 sales and widened losses.
- Several research firms have reiterated Buy ratings and raised price targets, while others trimmed targets, reflecting mixed but largely constructive analyst sentiment.
Shares Surge on Sector-Wide mRNA Rally
BioNTech shares are trading sharply higher, up about 19.64 percent to $110.97, driven by a broad rally across mRNA and oncology-focused biotech names after Moderna and Merck reported a positive late-stage trial result for their jointly developed mRNA cancer therapy in melanoma patients. The news has fueled renewed investor enthusiasm for mRNA-based oncology platforms more broadly, including BioNTech's own late-stage pipeline, which spans 14 ongoing trials.
Company Background and Recent Earnings
BioNTech (NASDAQ:BNTX) is a German multinational biotechnology company headquartered in Mainz, focused on developing immunotherapies and vaccines for cancer and infectious diseases, with an oncology pipeline spanning mRNA-based cancer vaccines, individualized neoantigen therapies, and CAR-T cell therapies. The move follows the company's second-quarter report, which showed revenue of 223.7 million euros beating the 157.8 million euro consensus, despite fading COVID-19 Vaccine sales and widened losses for the period.
Mixed Analyst Sentiment Amid Pipeline Catalysts
The rally also comes alongside confirmation that European regulators authorized the Pfizer-BioNTech variant-adapted COVID-19 vaccine for the 2026-2027 season, and news of a planned chief executive transition from Ugur Sahin to Guido Oelkers by February 2027. Analyst sentiment has been mixed following these developments, with Canaccord raising its price target to $142 and reiterating a Buy rating, while other research firms including Citi, Evercore ISI, and Berenberg trimmed their price targets, reflecting a largely constructive but divided view as investors weigh oncology pipeline catalysts against near-term COVID revenue declines.
The Bigger Picture
BioNTech shares are trading up about 19.64 percent to $110.97 amid a sector-wide mRNA rally sparked by Moderna and Merck's positive melanoma trial results. These are the verified facts as reported. Whether the advance holds may depend on how BioNTech's own oncology pipeline progresses and how the market weighs pipeline catalysts against declining COVID-19 vaccine revenue.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...